Clinical Effect Of Ilaprazole Sodium For Injection In The Treatment Of Peptic Ulcer Hemorrhage

Objective:To confirm the efficacy and safety of Ilaprazole sodium for injection in the treatment of peptic ulcer hemorrhage.Methods:100 cases of peptic ulcer bleeding patients admitted to my hospital from November 2014 to June 2016 were selected as the research objects.Between the two groups of cases of age.gender,height,weight,allergies,between the two groups ulcers and other gastrointestinal diseases history between the two groups,history of gastrointestinal bleeding between the two groups,drug treatment between the two groups,bleeding duration between the two groups and disease diagnosis,hematemesis,between the two groups of black,bleeding,blood transfusion amount,between the two groups of esophagus,stomach and duodenum examination and grading Forrest and helicobacter pylori infection,no statistical difference(P>0.05).Control dosing mode:1-3 days,omeprazole sodium for injection(astrazeneca pharmaceutical co.,LTD.,batch number:1403 a08,40 mg/a)40 mg,ql2h,with injected with saline mixture per 100 ml of liquids containing 40 mg,with filter infusion intravenous drip,drip off 30 minutes,simulating drugs:injection with physiological saline,100 ml/bag,disposable when the first agent.Group dosing mode:1-3 days,Ilaprazole sodium for injection(Lizhu group lizhu pharmaceutical factory,batch number:S140601,l0mg/piece)10 mg,q24h,a double agent.with injected with saline mixture per 100 ml of liquids containing 10 mg,with filter infusion intravenous drip,drip off 30 minutes,simulating drugs:Normal saline for injection,100ml/bag,q24h,12 hours apart from Ilaprazole sodium for injection.The total hemostasis rate of 72h under endoscopy,the total hemostasis rate of 72h in low-risk and high-risk patients and the drug safety evaluation were compared between the two groups.Results:the hemostasis rate of 72h population was 93.33%in the observation group and 87.5%in the control group.The hemostasis rate of 72h low-risk population was 94.87%in the observation group and 90.47%in the control group.The hemostasis rate of 72h high-risk population was 90.47%in the observation group and 84.21%in the control group.The effective rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 3.33%in the experimental group and 6.00%in the control group,and the difference between the two groups was statistically significant(P=0.0427).The incidence of leukopenia was 1.67%in the experimental group and 5.00%in the control group(P=0.0284).Conclusion:Ilaprazole sodium for injection once a day,twice the first dose,intravenous drip for 3 consecutive days,for the treatment of peptic ulcer bleeding,is better than omeprazole sodium 40mg,twice a day intravenous drip standard treatment,with good efficacy and safety.However,the number of patients involved in this trial is limited and it is part of the multi-center trial,so its persuasiveness is limited.It is necessary to wait for the results of the multi-center test to further confirm whether the efficacy and safety performance of Ilaprazole are better than that of omeprazole.And participate in the test research on the control of the drug only omeprazole,lack of other proton pump inhibitors,so the future clinical studies can be appropriately increase type other proton pump inhibitors as a control group in order to verify the curative effect advantage,and this test is only for the treatment of peptic ulcer bleeding,there is no treatment for other acid related diseases research.In order to fully demonstrate the superiority of its curative effect,future clinical research can be appropriately extended to other acid-related diseases.